Indivior (NASDAQ:INDV) Announces Earnings Results

Indivior (NASDAQ:INDV) announced its quarterly earnings data on Thursday. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32, Zacks reports. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. Indivior updated its FY 2025 guidance to EPS.

Indivior Stock Down 5.8 %

NASDAQ:INDV opened at $8.47 on Friday. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The stock has a market cap of $1.17 billion, a PE ratio of -24.19 and a beta of 0.73. The firm’s fifty day simple moving average is $11.51 and its 200-day simple moving average is $10.87.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on INDV shares. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective for the company.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.